Quantcast

Latest Atheroma Stories

2009-11-20 21:05:00

BEVERLY HILLS, Calif., Nov. 20 /PRNewswire/ -- In the study presented today at the American Heart Association Scientific Sessions in Orlando, Florida today, The Effect of Extended-release Niacin or Ezetimibe Added to Chronic Statin Therapy On Carotid Intima Media Thickness (ARBITER 6-HALTS), study found that: Adding the cholesterol drug niacin to a statin improved HDL ("good") cholesterol levels and significantly reduced carotid arterial plaque buildup measured with ultrasound within 8...

2009-11-18 14:50:57

Blood cholesterol levels improved, but arteries do not show it The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. In tests on 145 Baltimore-area men and women with existing atherosclerosis,...

2009-11-17 10:00:00

PHOENIX, Nov. 17 /PRNewswire/ -- The Heart & Vascular Center of Arizona today announced the availability of Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(i) coronary artery disease (CAD) in patients with stable chest pain. Corus CAD is a new genomic test launched in select U.S. markets, and the Heart & Vascular Center of Arizona is among the first institutions in the country to offer this first-of-its-kind gene expression test to...

2009-11-15 20:07:00

Study highlights: In patients with or at high-risk for coronary artery disease and LDL (bad cholesterol) treated with statins to < 100mg/dL but low HDL (good cholesterol), adding medication to raise HDL was compared with lowering LDL further. Patients were randomized to the addition of niacin (primarily to raise HDL), or ezetimibe (to further lower LDL cholesterol). Plaque buildup in the lining of the neck arteries was significantly reduced only in the niacin group. DUE TO AN EMBARGO...

2009-10-16 08:30:00

Parallel Phase 2 studies could expedite development timeline TSX Exchange Symbol: RVX CALGARY, Oct. 16 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) provided an outline yesterday at the Company's Annual General Meeting for shareholders highlighting the Company's clinical plan path for Resverlogix's lead drug, RVX-208, for the treatment of cardiovascular disease. Resverlogix outlined that the next two clinical studies will be performed in parallel....

2009-10-05 08:15:00

LOS ANGELES, Oct. 5 /PRNewswire/ -- According to a clinical study released in The American Journal of Cardiology, a daily serving of POM Wonderful 100% Pomegranate Juice may decrease the progression of arterial plaque in patients with elevated cardiovascular disease risk factors. The study was intended to see if POM Wonderful 100% Pomegranate Juice may slow the progression of intima-media thickness of the carotid artery (CIMT) in patients with moderate coronary heart disease risk. At 18...

2009-09-25 16:55:47

U.S. doctors say the untreated plaques causing unexpected heart attacks are not mild lesions as previously thought. The plaques are made up of fat, cholesterol, calcium and other substances found in the blood. The plaques at high risk of causing an adverse cardiovascular event had large plaque burdens and/or small lumen areas -- clear space in the vessel. These areas were invisible to the coronary angiogram but identifiable by intra-vessel ultra sound imaging, the researchers said. The...

2009-09-25 09:12:56

Late-breaking results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur. The trial, Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT), is the first prospective natural history study of atherosclerosis using multi-modality imaging to characterize the coronary tree....

2009-09-24 14:48:00

SAN FRANCISCO, Sept. 24 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, announced today imaging results from PROSPECT, the landmark 700 patient natural history study sponsored by Abbott and co-funded by Volcano. These data demonstrate the progression of cardiovascular disease via precise, intravascular imaging, and the ability of...

2009-09-24 14:25:00

SAN FRANCISCO, Sept. 24 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease. Results were presented today during the late-breaking clinical trials...